Altimmune (ALT) Income from Non-Controlling Interests (2019 - 2026)
Altimmune's (ALT) quarterly Income from Non-Controlling Interests came in at -$296000.0 in Q1 2026, down 886.67% year-on-year from $37627.1 in Q1 2025, and down 436.36% on a QoQ basis from $88000.0 in Q4 2025.
Altimmune (ALT) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Altimmune (ALT) has 8 years of Income from Non-Controlling Interests data on file, last reported at -$296000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 886.67% year-over-year to -$296000.0 in Q1 2026; TTM through Mar 2026 was -$221000.0, a 239.87% decrease from a year earlier, with the FY2025 full-year figure at $45000.0, up 45.16% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$296000.0, down from $88000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for ALT reached as high as $347000.0 in Q3 2024 and fell as low as -$296000.0 in Q1 2026.
- Historically, Income from Non-Controlling Interests has averaged -$11500.0 across 5 years, with a median of -$30500.0 in 2024.
- Across the five-year window, Income from Non-Controlling Interests slumped 12100.0% in 2022 and soared 519.64% in 2024, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $76000.0 in 2022, then soared by 57.89% to $120000.0 in 2023, then sank by 206.67% to -$128000.0 in 2024, then surged by 168.75% to $88000.0 in 2025, then sank by 436.36% to -$296000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$296000.0 in Q1 2026, $88000.0 in Q4 2025, and $23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Altimmune | 355.34 Mn | 355.34 Mn | - | -296,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -296,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Mar 31, 2025 | -30,000.00 |
| Dec 31, 2024 | -128,000.00 |
| Sep 30, 2024 | 347,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | -157,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Jun 30, 2023 | -79,000.00 |
| Mar 31, 2023 | 126,000.00 |
| Dec 31, 2022 | 76,000.00 |
| Sep 30, 2022 | -143,000.00 |
| Jun 30, 2022 | -120,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 5,000.00 |
| Dec 31, 2020 | -2,245.00 |